=0.7) with rs10995, which both could contribute to the observed genetic effects by affecting VASP mRNA expression. Conclusions-This study highlights the strength of using different omics to identify novel biomarkers of drug response and suggests VASP as a potential determinant of thiazide diuretics BP response.
H ypertension is the most common chronic disease and the primary cause of cardiovascular morbidity and mortality globally. 1 Studies have shown that the risk for coronary diseases and stroke doubles with every 20 mm Hg increase in systolic blood pressure (SBP) or 10 mm Hg increase in diastolic BP (DBP). 2 Accordingly, using antihypertensive medications for controlling BP substantially reduces cardiovascular risk and the overall mortality associated with hypertension. 3 Thiazide diuretics, including hydrochlorothiazide, are ranked among the most commonly prescribed drugs for the treatment of hypertension in the United States 4 and are highly recommended as first-line agents for most patients with uncomplicated essential hypertension. 5 Although they have been used as antihypertensives for more than half a century, the mechanism by which thiazide diuretics chronically lower BP has not been fully elucidated yet. 6 In addition, studies have shown that <50% of thiazide-treated patients achieve BP control. 7, 8 Even with the use of other antihypertension medications, acting on a variety of BP regulatory systems, only 44% of hypertension-treated patients achieve BP control. 9 Given these facts, it is clear that the current approach for selecting antihypertension medications is suboptimal, and more work is still needed to optimize the use of these drugs.
See Clinical Perspective
In the past decade, application of genome-wide association studies (GWAS) has advanced our understanding of the potential Background-Thiazide diuretics are among the most commonly prescribed antihypertensives. However, <50% of thiazidetreated patients achieve blood pressure (BP) control. Herein, we used different omics (genomics and transcriptomics) to identify novel biomarkers of thiazide diuretics BP response. Methods and Results-Genome-wide analysis included 228 white hypertensives with BP determined at baseline and after 9 weeks of hydrochlorothiazide. Single-nucleotide polymorphisms with P <5×10 −5 were prioritized according to their biological function, using RegulomeDB, haploreg, and Genome-Wide Annotation of Variants. The results from the prioritization approach revealed rs10995 as the most likely functional single-nucleotide polymorphism, among single-nucleotide polymorphisms tested, that has been associated with hydrochlorothiazide BP response. The rs10995 G-allele was associated with better BP response to hydrochlorothiazide versus noncarriers (∆ systolic BP/∆ diastolic BP: −12.3/−8.2 versus −6.8/−3.5 mm Hg, respectively, ∆ systolic BP P=3×10 −4 , ∆ diastolic BP P=5×10 −5 ). This association was replicated in independent participants treated with chlorthalidone. In addition, rs10995 G-allele was associated with increased mRNA expression of VASP (vasodilator-stimulated phosphoprotein). Moreover, baseline expression of the VASP mRNA was significantly higher in 25 good responders to hydrochlorothiazide compared with 25 poor responders (P=0.01). This finding was replicated in independent participants treated with chlorthalidone (P=0.04). Last, allelicspecific expression analysis revealed a significant but modest imbalance with rs10995 and rs10156, a single-nucleotide polymorphism in high linkage disequilibrium (r Pharmacogenomics of Thiazide Diuretics role of genetics in variable response to drugs. 10 Recently, we conducted a GWAS analysis in which we identified novel genetic regions associated with the BP response to hydrochlorothiazide, such as protein kinase C-α (PRKCA) and G-protein α-subunit-endothelin-3 (GNAS-EDN3). 11 In this study, we propose that there are additional true genetic contributors that have not met the stringent genome-wide statistical threshold, but they are difficult to ascertain statistically using genomics data alone, particularly with the small sample sizes of the globally available hypertension pharmacogenetics data sets. Thus, it is critical to leverage other information to effectively prioritize GWAS signals, increase replication rates, and better understand the mechanism underlying hydrochlorothiazide BP response.
Recent studies have shown that GWAS single-nucleotide polymorphisms (SNPs) associated with complex traits are more likely to be expression quantitative trait loci (eQTLs). 12, 13 In addition, studies have demonstrated that the majority (≈93%) of previously conducted GWAS findings lay in noncoding regions 14 and that these findings are significantly enriched in the regions that harbor functional elements, such as transcriptional factor binding sites, histone modification marked regions, DNase I hypersensitive sites, and eQTLs. 15, 16 Accordingly, we hypothesized that prioritizing the GWAS output based on regulatory functional signals that perturb gene expression might elucidate novel genetic signals affecting hydrochlorothiazide BP response. Investigating genes where these signals are involved might open new avenues for a better understanding of the molecular determinants of the BP response. Thus, we aimed in this study to use data from the Encyclopedia of DNA Elements project, such as transcriptional factor chromatin immunoprecipitation-seq, histone chromatin immunoprecipitation-seq, and DNase I hypersensitivity site data, along with publically available eQTL data, to prioritize and highlight novel genetic variants affecting the BP response to hydrochlorothiazide. In addition, we sought to use transcriptomics data to further confirm our genetic finding.
Methods

PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses)
The primary analysis included samples and data from participants recruited as part of the PEAR trial (Pharmacogenomic Evaluation of Antihypertensive Responses). 17 In brief, PEAR was a prospective, randomized, multicenter study with one of its primary aims being to evaluate the role of genetics on the BP response of hydrochlorothiazide-treated participants. PEAR recruited mild to moderate hypertensive participants, defined as participants with untreated DBP ≤110 and SBP ≤180. After enrollment, all participants had an average of 4-week washout period followed by a randomization to either a monotherapy of 12.5 mg per day hydrochlorothiazide or 50 mg per day atenolol (β-1-selective blocker) for a duration of 3 weeks, with the dose titrated upward for additional 6 weeks (ie, hydrochlorothiazide 25 mg per day or atenolol 100 mg per day) in participants with BP >120/70 mm Hg.
PEAR-2 Study (Pharmacogenomic Evaluation of Antihypertensive Responses-2)
We also used clinical data and biological samples from PEAR-2 (Pharmacogenomic Evaluation of Antihypertensive Responses-2) participants to validate and replicate our findings from the PEAR primary analysis. In brief, PEAR-2 was a prospective, multicenter, sequential monotherapy study 18 
Thiazide BP Response Measurement
The primary analysis of this study included 228 European American (white) participants from the PEAR study with their BP measured pre-hydrochlorothiazide (baseline) and 9 weeks post-hydrochlorothiazide therapy. In PEAR, BP at home, office, and ambulatory daytime and nighttime were measured, as previously described 17 and as explained in the online-only Data Supplement. For the analysis of the PEAR hydrochlorothiazide-treated participants included in this study, we used a composite weighted average of the home, office, and ambulatory daytime and nighttime, which we showed that it represents a more accurate measurement of BP response with a better signal:noise ratio and more power to identify genetic predictors of BP response. 19 The SNP replication analysis within this study included 185 white participants from the PEAR-2 study with their BP measured prechlorthalidone (baseline) and 8 weeks post-chlorthalidone therapy. Both home and office BP were measured, as previously described (Data Supplement).
18
Genotyping
Genome-wide genotyping for the PEAR participants was performed as previously described 11 and as explained in the Data Supplement. For PEAR-2, genotyping was conducted using Human Omni2.5 S BeadChip (Illumina, San Diego, CA). Participants from PEAR or PEAR-2 were excluded if sample genotype call rates were <95%. In addition, SNPs with a genotype call rates <95% were also excluded.
Gene Expression
Gene expression was measured using RNA-Seq analysis on both PEAR (discovery) and PEAR-2 (replication) white participants treated with hydrochlorothiazide and chlorthalidone, respectively. For PEAR RNA-Seq analysis, we collected whole blood samples at baseline from 50 white participants treated with hydrochlorothiazide. Participants were selected from the upper and lower quartiles of hydrochlorothiazide home DBP response (25 good BP responders and 25 poor BP responders). Similarly, for PEAR-2 gene expression, whole blood samples were collected at baseline from 50 white participants that were selected from the upper and lower quartiles of home DBP response to chlorthalidone (25 good BP responders and 25 poor BP responders) to conduct RNA-Seq analysis on these samples. Home DBP response was used for selection of participants for RNA-Seq analyses because it exhibits less variability and superior reproducibility compared with office BP response. 20 Of note, out of the 50 samples used for the RNA-Seq analysis in PEAR, 1 sample was removed because it did not pass quality control.
Details for the RNA-Seq analysis for both PEAR and PEAR-2 samples are described in the Data Supplement. In brief, a strand-specific protocol was used to prepare libraries, as previously described. 21 For data quality control purposes, read duplicates removal was implemented using Picard (http://picard.sourceforge.net) Mark Duplicates option. The 100 bp reads generated in the paired-end RNA sequencing were uniquely mapped to the human reference genome (hg19) using TopHat v2.0.10 allowing for 4 reads mismatches, read edit distance of 6, 1 mismatch in the anchor region of a spliced read, and a maximum of 5 multihits. Transcript assembly was performed using Cufflinks (v2.0.2), and gene expression values, reported in fragments per kilobase per million reads, were calculated using cuffdiff (v2.2.1). 22 
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Alternative tools for investigating differential gene expression were used to adjust for covariates such as age, sex, and baseline BP. First, we removed duplicate Binary Alignment/Map files from TopHat alignments, as an input to the function htseq-count, 23 to count the number of reads for each gene (Gencode gene annotation release 18). Counts were modeled to a negative binomial distribution using a generalized linear model implemented in edgeR 24 (Bioconductor R Package).
Statistical Analyses
Genomics Analysis
GWAS analysis was previously conducted 11 to test the association between dosage imputed genotype data with composite SBP and composite DBP responses to hydrochlorothiazide in 228 white participants from the PEAR study. PLINK software was used to run the analysis with adjustment for age, sex, pre-hydrochlorothiazide BP, and population substructure by considering the first and second principal components (PC1 and PC2) in all our analysis. In this study, we investigated SNPs with a P value <5×10 −5 from the GWAS of hydrochlorothiazide BP response, selected on the basis of quantile-quantile (Q-Q) plots showing that SNPs with P values <5×10 −5 deviated from expectation under the null hypothesis of no relationship between SNPs and hydrochlorothiazide BP response in PEAR white participants treated with hydrochlorothiazide ( Figure S1 in the online-only Data Supplement). Deviation from Hardy-Weinberg Equilibrium for the selected SNPs was tested using exact test, and SNPs with HardyWeinberg Equilibrium P value <1×10 − 5 were removed. The statistical analyses conducted in this study were performed with SAS (version 9.3; SAS Institute) and SPSS software (version 17.0; SPSS Inc).
SNPs Prioritization Approach
To address the aims of this study, an SNP prioritization approach was conducted as shown in Figure 1 . For the prioritization approach, we selected 103 SNPs (Table S1 ), representing 41 independent genetic signals, with P values <5×10 −5 from the GWAS analyses of both hydrochlorothiazide SBP and DBP responses conducted on PEAR whites. It is likely that among the 103 selected SNPs, true-positive SNPs might be in linkage disequilibrium (LD) with functional variants that are responsible for the significant association with hydrochlorothiazide BP response. Thus, we used rAggr webserver (http://raggr.usc.edu/) to select all SNPs in high LD (r 2 >0.8, according to Northern Europeans from Utah [Utah residents with Northern and Western European ancestry] population) with the 103 SNPs, within a distance of 500 kb, based on 1000 Genomes Project, phase 3 release. This step yielded 1082 SNPs which were then annotated and prioritized using 3 analytic tools: (1) RegulomeDB 25 (http://www.regulomedb.org/), (2) Genome-Wide Annotation of Variants (GWAVA) 26 (https://www.sanger.ac.uk/sanger/ StatGen Gwava), and (3) Haploreg v4.1 27 webserver (http://archive. broadinstitute.org/mammals/haploreg/haploreg.php). These 3 tools annotate SNPs based on high-throughput data sets from the Encyclopedia of DNA Elements project, along with other publically available eQTLs data sets, computational predictions, and manual annotations. More details about each tool are described in the Data Supplement.
In brief, the RegulomeDB has a scoring system that categorizes SNPs, ranging from 1 to 6, based on the degree of experimental or computational evidence and regulatory functional consequences of tested SNPs. For prioritization using RegulomeDB, we focused on SNPs with a score of 1 and 2 because the lower score indicates stronger evidence for an SNP to be located in a potentially functional region. Using GWAVA, SNPs were prioritized based on their transcription start site (TSS) score (calculated based on nearest TSS). We used GWAVA TSS score to prioritize our signals because it takes into account different regulatory annotations and not influenced by any single annotation. In addition, we selected SNPs with a TSS score ≥0.5, which represents the threshold used by GWAVA original authors to classify SNPs as functional. 26 Using Haploreg v4.1, we selected all SNPs that had been previously shown to affect gene expression (eQTLs). SNPs that overlap between the 3 annotation tools were then moved forward to be tested for replication in PEAR-2 whites treated with chlorthalidone, as explained below.
Replication
A general linear model was used to test the association between prioritized SNPs and chlorthalidone BP response in PEAR-2 whites, with adjustment for age, sex, pre-chlorthalidone BP, and PC1 and PC2.
Further Validation
For SNPs replicated in PEAR-2, we used Haploreg v4.1 to check whether these SNPs had been shown to be significantly associated with the mRNA expression levels of any genes. We then selected these genes and tested differences in their mRNA expression levels between PEAR hydrochlorothiazide good responders and poor responders. We further replicated our findings by testing the differences in mRNA expression levels, of the genes of interest, between PEAR-2 chlorthalidone good responders and poor responders.
We also tested replicated SNPs for allelic mRNA expression imbalance (AEI). SNP calls and allele-specific read counts were generated with SaMtools mpileup from the duplicate removed alignment file. 28 Analysis was conducted in individuals heterozygous for the relevant transcript SNPs in both PEAR and PEAR-2 thiazide diuretics-treated participants. χ 2 goodness-of-fit was applied to test if the allele ratio (minor allele/major allele) deviates from the expected ratio 0.5 (ie, when the 2 alleles are expressed equally). 29 Read counts for SNPs in high LD with each other were combined to yield a more accurate estimate of allelic ratios.
Last, for SNPs located in the 3′untranslated region of the gene, we tested them to check whether they interfere with miRNA target site using in silico tools such as MirSNP (http://bioinfo.bjmu.edu.cn/ mirsnp/search/) 30 and PolymiRTS database 3.0 (http://compbio.uthsc. edu/miRSNP/). 31 More details about those tools and the analysis approach are present in the Data Supplement.
Results
Characteristics of Study Participants and Thiazide Diuretics BP Response
Characteristics and thiazide diuretic BP responses of participants, included in the discovery and replication genetic analyses, are presented in Table 1 . We found that baseline characteristics such as age, sex, body mass index, and baseline BP were similar among PEAR and PEAR-2 participants. However, chlorthalidone-treated participants in PEAR-2 had greater BP lowering effects compared with hydrochlorothiazide-treated participants in PEAR, likely because of the fact that chlorthalidone is ≈1.5 to 2.0× as potent as hydrochlorothiazide therapy. Tables 2 and  3 , respectively. In addition, histograms describing the distribution of BP response among hydrochlorothiazide participants in PEAR and chlorthalidone participants in PEAR-2, who were included in the RNA-Seq analyses, are presented in Figure S2 . For PEAR RNA-Seq selected participants, baseline characteristics such as age, sex, body mass index, and baseline BP were not significantly different between good responders and poor responders to hydrochlorothiazide. However, in PEAR-2 RNA-Seq selected participants, age was marginally significant, and sex and baseline BP were both significantly different between chlorthalidone good responders and poor responders. Accordingly, we adjusted for age, sex, and baseline DBP in the analyses conducted using PEAR-2 RNA-Seq data. Of note, the mapping statistics of the RNA-Seq runs are presented in Table S2 .
SNPs Prioritization Approach
Out of the 103 SNPs, none of them deviated from HardyWeinberg Equilibrium (Table S1 ). Selecting SNPs in LD (r 2 >0.8) with the 103 SNPs provided a list of 1082 SNPs. Of the 1082 SNPs, 19 displayed a RegulomeDB score <3 (Table  S3) . Out of those 19, rs10995 located in the 3′untranslated region of the vasodilator-stimulated phosphoprotein gene (VASP) was the top prioritized SNP with a RegulomeDB score of 1 d. Testing the 1082 SNPs in GWAVA identified 29 SNPs with a TSS score ≥0.5 (Table S4) . Again, GWAVA identified rs10995 as the top prioritized SNP with a score of 0.87. Using Haploreg v4.1, we were able to annotate 290 SNPs out of the 1082 SNPs as eQTLs. Visualizing the combined results of these different tools ( Figure S3 and Table S5 ) highlights rs10995 as the only overlapping and top prioritized signal associated with hydrochlorothiazide BP response. Thus, we tested the rs10995 association for replication in PEAR-2 whites treated with chlorthalidone.
Replication and Further Validation
The minor allele frequency of rs10995 G>A SNP in PEAR and PEAR-2 whites was 25.6% and 25.9%, respectively. Testing the rs10995 SNP in PEAR-2 whites revealed a significant For PEAR, composite BP response was generated using the weighted average of the home, office, ambulatory daytime, and nighttime BP responses. BMI indicates body mass index; DBP, diastolic blood pressure; PEAR, Pharmacogenomic Evaluation of Antihypertensive Responses; and SBP, systolic blood pressure.
*In PEAR good responders, 1 sample failed the RNA-Seq quality control procedures and was not included in the study. (Figure 2) , with adjustment for baseline BP, age, sex, and PC1 and PC2. Although we adjusted for baseline BP in our analysis, we also tested the association between rs10995 and baseline BP in PEAR and PEAR-2 participants included in this study. Our results showed no association between the rs10995 and baseline BP measured in PEAR (DBP=0.42, SBP=0.22) and PEAR-2 (DBP=0.17, SBP=0.88). In addition, the in silico analysis using Haploreg v4.1 shows that rs10995 is associated with the mRNA expression levels of 4 genes (VASP, FOSB, GPR4, and KLC3; Table S6 ). Therefore, we tested baseline expression levels of those genes between hydrochlorothiazide good responders and poor responders in PEAR participants. Out of the 4 genes, only VASP displayed a significantly different mRNA levels between hydrochlorothiazide good responders and poor responders (P=0.01; Figure 3A ; Table S7 ). We found that hydrochlorothiazide good responders had higher VASP mRNA levels at baseline compared with poor responders. This association was replicated in the same direction in PEAR-2 participants treated with chlorthalidone (P=0.04; Figure 3B ; Table S7 ). However, after adjustment for age, sex, and baseline BP using EdgeR, the association weakened (adjusted P=0.12; Table S8 ).
We also found a significant association between rs10995 and VASP mRNA expression at baseline in PEAR-2 (P=5×10 −3 ) and a trend toward significance in PEAR participants (P=0.06). Our analysis showed that the rs10995 G/G genotype carriers (with better response to hydrochlorothiazide) had higher expression levels of VASP mRNA at baseline compared with G/A and A/A genotype carriers ( Figure S4 ). This finding was supported by publically available eQTL data showing the same effect of the rs10995 G-allele on the VASP mRNA expression in several tissues (Table S6) . We also sought to test whether allelic VASP mRNA expression is higher in the presence of the rs10995 G-allele compared with the A-allele. For rs10995, of 39 heterozygous samples tested from PEAR and PEAR-2, 2 samples had G/A-allele ratios >2-fold, evidence of AEI, and 18 samples displayed a ≥1.2-fold change (Figure S5) , although the remaining sample did not show allelic ratios suggestive of AEI. Because of inherent noise in allelic RNA ratio analysis, it is not possible to assign the presence of AEI unambiguously. 33 Thus, we tested the SNPs in high LD (r 2 >0.8) with rs10995 (Table S9 ) and all SNPs in the exon region of the VASP gene with coverage >50 reads (Table S10) . From this analysis, we only focused on SNPs that have been shown in at least 2 heterozygous samples to have an AEI fold change >1.3. According to this criterion, we found 2 SNPs, rs10156 and rs546716916, with samples that had a change between their reference and variant alleles counts >1.3. The latter SNP is a rare SNP located 78 bp away from the rs10995 SNP, but it is not in LD with the rs10995 SNP ( Figure S6 ). While for the rs10156 SNP, we found that it is in high LD with the rs10995 SNP (r 2 =0.7, D′=1) and laying 173 bp away from the rs10995 signal. rs10156 T>C SNP had higher read counts and displayed allelic ratios in the same direction as rs10995 in the vast majority of samples ( Figure S7 ), suggesting that the copy Figure 2 . Effect of the rs10995 polymorphism on the blood pressure response of whites treated with thiazide diuretics in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and PEAR-2 studies. Blood pressure responses were adjusted for baseline blood pressure, age, sex, and first and second principal components (PC1 and PC2). P values represented are for contrast of adjusted means between different genotype groups. Error bars represent SE of the mean. *One-sided P value based on a 1-sided hypothesis tested in the replication study. A, Systolic blood pressure (SBP) response to hydrochlorothiazide (HCTZ) in the PEAR study. B, Diastolic blood pressure (DBP) response to HCTZ in the PEAR study. C, SBP response to chlorthalidone (CLT) in the PEAR-2 study. D, DBP response to CLT in the PEAR-2 study. Pharmacogenomics of Thiazide Diuretics of the gene containing the reference GT-alleles is expressed more than the AC-alleles with the 2 SNPs combined with a mean log 2 allelic expression ratio of 0.48 (P=0.004). These results support a finding of AEI, although we cannot ascertain whether rs10995 or rs10156 or both alter mRNA expression.
Last, because the rs10995 SNP is located in the 3′untrans-lated region of the VASP gene, we tested whether rs10995 SNP interferes with a miRNA binding site. Both MirSNP and PolymiRTS database 3.0 databases indicate that the rs10995 G-allele creates a new binding site for miRNA 3127-3p, which enhance its binding to VASP mRNA compared with the A-allele (Table S11) . This result suggests an additional mechanism of action that could account at least in part for the observed clinical associations.
Discussion
Thiazide diuretics have been the mainstay antihypertension therapy for years and are currently ranked among the most commonly prescribed first-line antihypertension in the United States. Despite their widespread use, a wide interindividual variability in response to thiazide diuretics has been reported, which has stimulated interest in identifying predictors that can be used for optimizing the BP response to this therapy. Over the past years, results from GWAS have advanced our understanding of the potential role of genetics on the interindividual variability in response to different drugs, including thiazide diuretics. 6, 11 However, GWAS stringent statistical thresholds hinder the discovery of additional true genetic variants, particularly with the small sample sizes of the globally available hypertension pharmacogenetic studies. Thus, in this study, we sought to identify additional novel genetic variants associated with thiazide diuretics BP response by leveraging functional data generated from the Encyclopedia of DNA Elements project and other publically available eQTL data sets. We hypothesized that this approach would help prioritize the genetic signals from the GWAS and increase the chances of refining and identifying additional true signals that might be missing.
In this study, out of the 1082 SNPs tested in our prioritization analysis, we identified and replicated the rs10995 in the VASP gene as a novel genetic signal with clinically relevant effects on the BP response of thiazide diuretics. In addition, using RNASeq data from thiazide diuretics-treated individuals showed that the rs10995 SNP represents a VASP eQTL. Moreover, we found that hydrochlorothiazide good BP responders had higher baseline expression levels of the VASP gene compared with poor responders, which suggests that VASP might be a potential predictor of thiazide diuretics BP response. This finding was replicated in PEAR-2 participants treated with chlorthalidone, where chlorthalidone good BP responders had significantly higher VASP mRNA levels at baseline compared with poor responders. Although this association weakened after adjustment for age, sex, and baseline BP, this might be attributed to the small sample size used for the RNA-Seq analysis.
For further validation, we also tested whether rs10995 SNP and an adjacent SNP in high LD, rs10156, display allelespecific VASP mRNA expression. Taken together, the allelic ratio results demonstrate the presence of AEI as a marker of a genetic variant, most likely rs10995 or rs10156, or both. Of note, we did not have the rs10156 among the genotyped or imputed SNPs in our GWAS data; thus, we were not able to test its association with thiazide diuretics BP response. Future studies should consider testing this SNP to check its association with hydrochlorothiazide BP response. Last, in silico testing reveals that rs10995 minor allele enhances the binding of miRNA 3127-3p in the 3′untranslated region. Although these results are intriguing, more experimental work is needed to test the interaction between rs10995 SNP and miRNA 3127-3p and its clinical relevance. 
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VASP is highly expressed in vascular endothelial cells, smooth muscle cells, and platelets. 34, 35 As a member of the ENA/VASP protein family, VASP is involved in actin polymerization, actin cytoskeleton regulation, and intracellular pathways of integrin-extracellular matrix interaction 36 pathways involved in the mechanism underlying smooth muscle contraction and BP regulation. 37, 38 VASP has also been well characterized as a substrate for cAMP-and cGMP-dependent protein kinases, 39 known for their role in regulating contraction of vascular smooth muscle. 40 In addition, VASP phosphorylation has been implicated in various cellular responses ranging from endothelial cell permeability and angiogenesis 41, 42 to platelet aggregation and secretion. 43, 44 Moreover, it serves as a biochemical marker for monitoring nitric oxide-stimulated soluble guanylyl cyclase/cGMP-dependent protein kinase type I pathway, 45 which is involved in BP regulation, vascular remodeling and platelet, cardiac and kidney function. [46] [47] [48] Collectively, the results of this study along with literature evidence support the hypothesis that VASP might be involved in the BP lowering mechanism of thiazides and might serve as an important determinant of thiazide diuretics BP response. Future replication of the findings presented in this study in large well-designed studies is needed to confirm their use in guiding the selection of thiazide diuretics for a better control on BP response. In addition, conducting mechanistic studies on the VASP gene might provide insight into the mechanism underlying thiazide diuretics BP response.
Our study has several limitations. First, the small sample sizes used for the genetic and transcriptomics analyses may have limited our power to identify additional novel markers and replicate some of our genetic and transcriptomics signals. Second, we used whole blood-based RNA for the RNA-Seq analyses, which might not be the most relevant tissue for thiazide BP response. However, response to antihypertension drugs might arise from a variety of target tissues. Thus, it is difficult to select a specific tissue for testing the expression of BP genes because BP genes might be expressed in blood, heart, brain, kidney, or any other specific tissue. In addition, such tissues are essentially impossible to obtain from otherwise healthy hypertensive individuals. Last, whole blood samples can have different ratios of cell types, which may result in artifacts of differences in expression levels of genes that are differentially expressed between cell types. However, we did not measure differences in cell-type distributions in blood for our RNA-seq runs. Thus, we were not able to account for possible changes in cell-type composition. Although it is possible that differences in cell-type distribution could affect gene expression levels, however, this happens particularly with a disease state or drug treatment suspected of changing cell-type content, which is not the case with the drug treatment regimen used in this study.
Our study also has several strengths. The prioritization approach used in this study was successful in identifying a novel genetic signal that we were not able to identify using traditional approaches for analyzing the GWAS output. Our findings from this approach support the hypothesis that not all SNPs are equal 49 and mandate the importance of using functional annotations to better prioritize the GWAS output and increase the chances of identifying and replicating true signals associated with variability in drug response. We think that using such an approach could help us to take forward the large investment in GWAS and convert the output of this approach to identify additional genetic variants and biologically relevant pathways associated with drug response.
In summary, to our knowledge, this is the first study to highlight the association between the VASP gene and thiazide diuretics BP response. This study illustrates the power of using the publically available Encyclopedia of DNA Elements data and eQTL data sets to prioritize the GWAS output and increase the probability of identifying novel genetic variants underlying drug response. Future use of these publically available data might give us more insight into the mechanism underlying BP response, which might facilitate the development of new drugs and therapeutic approaches that can be used for optimizing antihypertensive BP response.
